Elias Jabbour
A5049385583- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Epigenetics and DNA Methylation
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Pneumocystis jirovecii pneumonia detection and treatment
- Retinoids in leukemia and cellular processes
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer therapeutics and mechanisms
- Hematological disorders and diagnostics
- HIV/AIDS drug development and treatment
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
The University of Texas MD Anderson Cancer Center
2016-2025
McGill University
2023-2024
MD Anderson Cancer Center Madrid
2024
McGill University Health Centre
2021-2024
John Wiley & Sons (United States)
2016-2023
Hudson Institute
2016-2023
Massachusetts General Hospital
2015-2023
Harvard University
2023
Mayo Clinic
2016-2023
Imperial College Healthcare NHS Trust
2023
Abstract BACKGROUND Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger and may not apply to elderly AML. Many investigators oncologists advocate, at times, only supportive care or frontline single agents, Phase I–II studies, low‐intensity regimens, ‘targeted’ therapies. However, baseline expectations for outcomes of AML ‘standard’ well defined. The aim was develop prognostic...
Abstract Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this single-arm trial, in which patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were treated azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously nivolumab 3 mg/kg on 14, every 4 6 weeks. For the seventy who treated, median age was 70 years (range, 22–90) number of prior therapies...
Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations indicated potential synergistic interaction their combination.
Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), efficacy lower intensity combinations for treatment-naïve elderly AML patients. VEN treatment R/R have not been previously reported.All patients (including AML, myelodysplastic syndrome (MDS), blastic plasmacytoid dendritic cell neoplasm (BPDCN)) treated with the salvage setting were reviewed.Forty-three median age 68 (range, 25-83) (91%), MDS (5%), or BPDCN...
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% newly diagnosed in adults.CML characterized by balanced genetic translocation, t(9;22)(q34;q11.2), involving fusion the Abelson gene (ABL1) from chromosome 9q34 breakpoint cluster region (BCR) on 22q11.2. This rearrangement known as Philadelphia chromosome. The molecular consequence this translocation generation BCR-ABL1 oncogene, which turn...
Abstract Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization clonal architecture essential to understand the evolutionary history tumor development and its association with treatment resistance. Here, using single-cell DNA sequencing, we report mutational histories 123 acute myeloid leukemia (AML) patients. The data reveals cell-level mutation co-occurrence enables reconstruction characterized linear branching patterns evolution,...
BACKGROUND CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin, a monoclonal antibody bound to calicheamicin, is active ALL. METHODS Patients refractory‐relapsed ALL received treatment inotuzumab. The first 49 single‐dose, intravenous inotuzumab at doses 1.3 1.8 mg/m2 every 3 4 weeks. In the next 41 patients, schedule was modified weekly dose 0.8 on day 1 and 0.5 days 8 15, weeks, based higher vitro efficacy more frequent exposure....
Background Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate used for adults with relapsed/refractory B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO‐VATE) previously reported improved outcomes InO versus standard‐of‐care (SoC) chemotherapy. This article reports the final INO‐VATE results (≥2 years of follow‐up) additional analyses patient characteristics associated outcomes. Methods Between...
Phenotypic characterization of immune cells in the bone marrow (BM) patients with acute myeloid leukemia (AML) is lacking.T-cell infiltration was quantified on BM biopsies from 13 AML, and flow cytometry performed aspirates (BMAs) 107 AML who received treatment at The University Texas MD Anderson Cancer Center. authors evaluated expression inhibitory receptors (programmed cell death protein 1 [PD1], cytotoxic T-lymphocyte antigen 4 [CTLA4], lymphocyte-activation gene 3 [LAG3], T-cell...
The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known.Data from 87 MDS (n=67) and chronic myelomonocytic leukemia (n=.20) regimens were reviewed.After a median follow-up 21 months failure, 13 (15%) remained alive; the survival was 4.3 months, estimated 12-month rate 28%. rates 27%, 33%, respectively, for high-risk, intermediate-2-risk, intermediate-1-risk disease (P=.99) by International Prognostic Scoring System. 100%, 54%, 41%, 18%, low-risk,...